I. Expression across cell types
Name | Number of supported studies  | Average coverage | |
|---|---|---|---|
| endothelial cell | 4 studies | 20% ± 2% | |
| type I pneumocyte | 3 studies | 23% ± 5% | |
| hepatocyte | 3 studies | 38% ± 26% |
Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| endothelial cell | 4 studies | 20% ± 2% | |
| type I pneumocyte | 3 studies | 23% ± 5% | |
| hepatocyte | 3 studies | 38% ± 26% |
Insufficient scRNA-seq data for expression of HYAL1 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| liver | 100% | 10127.01 | 226 / 226 | 98% | 103.62 | 399 / 406 |
| kidney | 100% | 4146.55 | 89 / 89 | 96% | 44.60 | 867 / 901 |
| pancreas | 92% | 516.21 | 301 / 328 | 86% | 28.00 | 153 / 178 |
| lung | 100% | 3286.35 | 578 / 578 | 65% | 13.80 | 756 / 1155 |
| esophagus | 95% | 577.81 | 1370 / 1445 | 63% | 14.46 | 116 / 183 |
| adrenal gland | 100% | 2017.93 | 258 / 258 | 57% | 12.47 | 132 / 230 |
| uterus | 99% | 884.81 | 168 / 170 | 53% | 9.38 | 242 / 459 |
| stomach | 98% | 1350.42 | 351 / 359 | 46% | 9.08 | 132 / 286 |
| intestine | 91% | 557.39 | 882 / 966 | 50% | 13.26 | 262 / 527 |
| thymus | 99% | 914.00 | 649 / 653 | 32% | 2.35 | 196 / 605 |
| breast | 98% | 943.47 | 450 / 459 | 12% | 1.47 | 133 / 1118 |
| bladder | 86% | 466.52 | 18 / 21 | 24% | 4.82 | 120 / 504 |
| skin | 77% | 1476.68 | 1385 / 1809 | 26% | 3.99 | 121 / 472 |
| spleen | 100% | 9994.77 | 241 / 241 | 0% | 0 | 0 / 0 |
| ureter | 0% | 0 | 0 / 0 | 100% | 13.75 | 1 / 1 |
| heart | 100% | 2562.30 | 860 / 861 | 0% | 0 | 0 / 0 |
| adipose | 99% | 944.04 | 1189 / 1204 | 0% | 0 | 0 / 0 |
| prostate | 89% | 478.57 | 219 / 245 | 6% | 0.37 | 30 / 502 |
| muscle | 86% | 524.38 | 692 / 803 | 0% | 0 | 0 / 0 |
| tonsil | 0% | 0 | 0 / 0 | 64% | 8.59 | 29 / 45 |
| ovary | 46% | 216.42 | 83 / 180 | 15% | 1.67 | 63 / 430 |
| blood vessel | 53% | 272.26 | 708 / 1335 | 0% | 0 | 0 / 0 |
| brain | 33% | 113.21 | 867 / 2642 | 2% | 0.11 | 11 / 705 |
| eye | 0% | 0 | 0 / 0 | 21% | 2.42 | 17 / 80 |
| lymph node | 0% | 0 | 0 / 0 | 3% | 0.31 | 1 / 29 |
| peripheral blood | 2% | 9.06 | 19 / 929 | 0% | 0 | 0 / 0 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| GO_0045927 | Biological process | positive regulation of growth |
| GO_0071467 | Biological process | cellular response to pH |
| GO_0006954 | Biological process | inflammatory response |
| GO_0030207 | Biological process | chondroitin sulfate catabolic process |
| GO_0030307 | Biological process | positive regulation of cell growth |
| GO_0045766 | Biological process | positive regulation of angiogenesis |
| GO_0009615 | Biological process | response to virus |
| GO_0005975 | Biological process | carbohydrate metabolic process |
| GO_0071347 | Biological process | cellular response to interleukin-1 |
| GO_0045785 | Biological process | positive regulation of cell adhesion |
| GO_0030214 | Biological process | hyaluronan catabolic process |
| GO_0006027 | Biological process | glycosaminoglycan catabolic process |
| GO_0060272 | Biological process | embryonic skeletal joint morphogenesis |
| GO_0071493 | Biological process | cellular response to UV-B |
| GO_1900106 | Biological process | positive regulation of hyaluranon cable assembly |
| GO_1900087 | Biological process | positive regulation of G1/S transition of mitotic cell cycle |
| GO_0071356 | Biological process | cellular response to tumor necrosis factor |
| GO_0050679 | Biological process | positive regulation of epithelial cell proliferation |
| GO_0030212 | Biological process | hyaluronan metabolic process |
| GO_0046677 | Biological process | response to antibiotic |
| GO_0000302 | Biological process | response to reactive oxygen species |
| GO_0030213 | Biological process | hyaluronan biosynthetic process |
| GO_0051216 | Biological process | cartilage development |
| GO_0044344 | Biological process | cellular response to fibroblast growth factor stimulus |
| GO_0010634 | Biological process | positive regulation of epithelial cell migration |
| GO_0036120 | Biological process | cellular response to platelet-derived growth factor stimulus |
| GO_0030308 | Biological process | negative regulation of cell growth |
| GO_0005615 | Cellular component | extracellular space |
| GO_0031410 | Cellular component | cytoplasmic vesicle |
| GO_0005764 | Cellular component | lysosome |
| GO_0070062 | Cellular component | extracellular exosome |
| GO_0005737 | Cellular component | cytoplasm |
| GO_0036117 | Cellular component | hyaluranon cable |
| GO_0043202 | Cellular component | lysosomal lumen |
| GO_0004415 | Molecular function | hyalurononglucosaminidase activity |
| GO_0052757 | Molecular function | chondroitin hydrolase activity |
| GO_0050501 | Molecular function | hyaluronan synthase activity |
| GO_0001618 | Molecular function | virus receptor activity |
| Gene name | HYAL1 |
| Protein name | Hyaluronidase (EC 3.2.1.35) Hyaluronidase-1 (Hyal-1) (EC 3.2.1.35) (Hyaluronoglucosaminidase-1) (Lung carcinoma protein 1) (LuCa-1) |
| Synonyms | LUCA1 hCG_17459 |
| Description | FUNCTION: May have a role in promoting tumor progression. May block the TGFB1-enhanced cell growth. . |
| Accessions | ENST00000395144.7 [Q12794-1] ENST00000457214.6 [Q12794-3] ENST00000320295.12 [Q12794-1] ENST00000266031.8 [Q12794-1] C9JB49 Q12794 ENST00000452672.1 A0A0S2Z3Q0 ENST00000418723.1 A0A024R2X3 ENST00000618175.4 [Q12794-1] ENST00000395143.6 [Q12794-2] ENST00000447605.2 [Q12794-5] C9JRK1 |
